VAXum

VAXum is a Swiss biotechnology company specializing in the design and development of next-generation vaccines through its proprietary Self-Assembling Protein Nanoparticle (SAPN) platform. This technology enables the creation of synthetic nanoparticles that mimic the size and symmetry of natural viruses, presenting antigens in a highly organized manner to trigger robust immune responses. The company's primary focus is on addressing high-burden infectious diseases such as HIV and Malaria, where traditional vaccine approaches have faced significant hurdles. VAXum's modular platform also allows for rapid adaptation to emerging pathogens, as demonstrated by its research into SARS-CoV-2 candidates. By leveraging structural biology and nanotechnology, the company aims to deliver potent, cost-effective, and stable vaccine solutions for global health challenges.